AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

12,170.00p
   
  • Change Today:
    108.00p
  • 52 Week High: 12,270.00
  • 52 Week Low: 9,501.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.22m
  • Volume: 867,627
  • Market Cap: £188,662m
  • RiskGrade: 123
  • Beta: 0.00

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.
Registrars: Equiniti
Brands: Losec, Prilosec, Nexium, Crestor

Key Personnel

Senior Independent Non-Executive Director: Philip A J Broadley
CEO and Executive director: Pascal Soriot
CFO & Executive Director: Aradhana Sarin
Chairman: Michel Demare
Independent Non-Executive Director: Diana Layfield
Independent Non-Executive Director: Tony Mok
Independent Non-Executive Director: Nazneen Rahman
Independent Non-Executive Director: Sheri McCoy
Independent Non-Executive Director: Euan Ashley
Independent Non-Executive Director: Deborah DiSanzo
Non-Executive Dir: Anna Manz, Marcus Wallenberg, Andreas Rummelt

Contact Details

Address: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge,United Kingdom, CB2 0AA
Phone: +44 (0)20 3749 5000
Fax: +44 (0)20 7604 8151
Website: http://www.astrazeneca.com

Listings

Sector: Pharma and Biotech(LSE)
Index: FTSE 100, FTSE 350, FTSE All-Share
Overseas Listings: BATSLON:AZNL
ISIN: GB0009895292

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 12,170.00p
Change Today 108.00p
% Change 0.90 %
52 Week High 12,270.00
52 Week Low 9,501.00
Volume 867,627
Shares Issued 1,550.22m
Market Cap £188,662m
Beta 0.00
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.49% below the market average92.49% below the market average92.49% below the market average92.49% below the market average92.49% below the market average
92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average
Price Trend
60.64% above the market average60.64% above the market average60.64% above the market average60.64% above the market average60.64% above the market average
82.14% above the sector average82.14% above the sector average82.14% above the sector average82.14% above the sector average82.14% above the sector average
Income
91.22% below the market average91.22% below the market average91.22% below the market average91.22% below the market average91.22% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
82.84% above the market average82.84% above the market average82.84% above the market average82.84% above the market average82.84% above the market average
94.44% above the sector average94.44% above the sector average94.44% above the sector average94.44% above the sector average94.44% above the sector average

What The Brokers Say

Strong Buy 8
Buy 15
Neutral 5
Sell 0
Strong Sell 1
Total 29
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 22-Feb-24 10-Aug-23
Paid 25-Mar-24 11-Sep-23
Amount 197.00¢ 93.00¢

Trades for 01-May-2024

Time Volume / Share Price
16:02 0 @ 12,156.00p
15:54 0 @ 12,156.00p
15:54 0 @ 12,156.00p
15:53 0 @ 12,156.00p
15:52 0 @ 12,152.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page